Abstract: Objective To evaluate the clinical efficacy and safety of endoscopic selective varices devascularization (ESVD) combined with oral carvedilol in the treatment for patients with esophageal and gastric varices bleeding (EGVB). Methods A retrospective analysis was performed on 40 cirrhosis patients with EGVB. According to different methods of treatment, 22 patients were selected into ESVD group, and 18 patients were selected into carvedilol combined ESVD group, respectively. The rate of rebleeding, mortality, endoscopic improvement rate and the incidence of complications were compared between two groups. Results The rebleeding rates within 2 weeks after treatment of ESVD group and combined treatment group were 36.4% (8/22) and 11.1% (2/18), respectively, which was no significant difference (P>0.05). The rebleeding rate within 6 months after treatment of combined treatment group was 22.2% (4/18), which was significantly lower than that of ESVD group (54.5%, 12/22) (P<0.05). The rates of hemorrhage-related death within 6 months after surgery in ESVD group and combined treatment group were 9.1% (1/22) and 5.6% (1/18), respectively, and the overall mortality were 9.1% (1/22) and 5.6% (1/18), respectively, which was no statistically significant (P>0.05). One month after treatment, endoscopic improvement rates of ESVD group and combined treatment group were 59.1% (13/22) and 88.8% (16/18) respectively, which was statistically significant (P<0.05). Six months after treatment, endoscopic improvement rates of ESVD group and combined treatment group were 54.5% (12/22) and 88.8% (16/18) respectively, which was statistically significant (P<0.05). No serious complication occurred in both groups during the follow-up period. Conclusion The efficacy and safety of ESVD combined with oral carvedilol are more available in the treatment for patients with EGVB, which is worthy clinical promotion.

Key words: Liver cirrhosis, Esophageal and gastric varices bleeding, Endoscopic selective varices devascularization, Carvedilol